Precision Therapeutics announces that four abstracts on the ChemoFx® accepted for poster presentation at the International Gynecologic Cancer Society (IGCS) Annual Meeting
Precision Therapeutics announces that four abstracts on the ChemoFx® in vitro drug response marker have been accepted for poster presentation at the International Gynecologic Cancer Society (IGCS) Annual Meeting, which will be held in Vancouver October 13-16, 2012.
The first abstract, submitted by Dr. Charles A. Leath III and titled, Evaluation of a Prospective Observational Trial Utilizing The ChemoFx® Chemosensitivity and Resistance Assay (CSRA) In Epithelial Ovarian Cancer,demonstrates physician practice patterns as well as the clinical utility of ChemoFx for patients with epithelial ovarian cancer.
An abstract submitted by Dr. Perry W. Grigsby and titled, In Vitro Chemoresponse Analysis and Clinical Outcomes in Cervical Cancer,reports the association between ChemoFx test results and recurrence-free survival (RFS) of cervical cancer patients. This analysis further supports the use of ChemoFx for helping with treatment decisions for cervical cancer patients.